S. Ribault , P. Rippert , G. Bassez , T. Duong , C. Vuilllerot
{"title":"213P 1 型肌张力营养不良症运动功能测量(MFM)对变化的敏感性","authors":"S. Ribault , P. Rippert , G. Bassez , T. Duong , C. Vuilllerot","doi":"10.1016/j.nmd.2024.07.064","DOIUrl":null,"url":null,"abstract":"<div><div>Myotonic dystrophy type 1 (DM1) is a hereditary multisystemic disease characterized by progressive muscle wasting, heart conduction abnormalities, early-onset cataract, and endocrinological disorders. It is caused by a non-coding CTG repeat expansion in the DMPK gene. With new therapeutic advancements and ongoing clinical trials focusing on siRNA, antisense oligonucleotides or gene therapy, there is an imperative to identify a suitable clinical outcome to assess motor function in DM1. The Motor Function Measure is a 3-dimensional quantitative scale (D1: standing/transfers, D2: Proximal/axial, D3: Distal) designed to monitor motor function in patients with neuromuscular diseases encompassing the spectrum of the disease regardless disease severity or functional level. This is a multicentric retrospective review of adults and children with a genetic diagnosis of DM1. Included subject were male or female DM1 patients with the availability of at least 2 MFM32 scores at 1 year. MFM32’s mean slope of change and standard response mean (SRM) were calculated. 343 subjects were included. At the first MFM mean age was 36.3 years (+/- 16.1, min: 6.1yo; max: 71.8yo), and mean MFM32 scores were 69.1%+/-25.1, 91.9%+/-9.1, 90.8.1%+/-8.4, and 82.4%+/-13.8 for D1, D2, D3 and Total score respectively. Average time between first and last assessments was 5.1 years (+/- 3.6, min: 1 y; max: 15.9yo). MFM32’s yearly mean slope of change was -2.25% (+/-3.86) for D1, -1.09% (+/-3.50) for D2, -0.54% (+/-2.95) for D3, -1.44 (+/-2.46) for total score. SRM was -0.58 for D1, -0.31 for D2, -0.18 for D3, -0.59 for total score. Understanding the change over time in a natural history cohort is important to understand the impact of change against a changing disease landscape. We showed MFM32’s responsiveness to change most relevant in the standing and transfer domain (D1) and MFM total score than the more proximal or distal domains.</div></div>","PeriodicalId":19135,"journal":{"name":"Neuromuscular Disorders","volume":"43 ","pages":"Article 104441.55"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"213P Sensitivity to change of the motor function measure (MFM) in myotonic dystrophy type 1\",\"authors\":\"S. Ribault , P. Rippert , G. Bassez , T. Duong , C. Vuilllerot\",\"doi\":\"10.1016/j.nmd.2024.07.064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Myotonic dystrophy type 1 (DM1) is a hereditary multisystemic disease characterized by progressive muscle wasting, heart conduction abnormalities, early-onset cataract, and endocrinological disorders. It is caused by a non-coding CTG repeat expansion in the DMPK gene. With new therapeutic advancements and ongoing clinical trials focusing on siRNA, antisense oligonucleotides or gene therapy, there is an imperative to identify a suitable clinical outcome to assess motor function in DM1. The Motor Function Measure is a 3-dimensional quantitative scale (D1: standing/transfers, D2: Proximal/axial, D3: Distal) designed to monitor motor function in patients with neuromuscular diseases encompassing the spectrum of the disease regardless disease severity or functional level. This is a multicentric retrospective review of adults and children with a genetic diagnosis of DM1. Included subject were male or female DM1 patients with the availability of at least 2 MFM32 scores at 1 year. MFM32’s mean slope of change and standard response mean (SRM) were calculated. 343 subjects were included. At the first MFM mean age was 36.3 years (+/- 16.1, min: 6.1yo; max: 71.8yo), and mean MFM32 scores were 69.1%+/-25.1, 91.9%+/-9.1, 90.8.1%+/-8.4, and 82.4%+/-13.8 for D1, D2, D3 and Total score respectively. Average time between first and last assessments was 5.1 years (+/- 3.6, min: 1 y; max: 15.9yo). MFM32’s yearly mean slope of change was -2.25% (+/-3.86) for D1, -1.09% (+/-3.50) for D2, -0.54% (+/-2.95) for D3, -1.44 (+/-2.46) for total score. SRM was -0.58 for D1, -0.31 for D2, -0.18 for D3, -0.59 for total score. Understanding the change over time in a natural history cohort is important to understand the impact of change against a changing disease landscape. We showed MFM32’s responsiveness to change most relevant in the standing and transfer domain (D1) and MFM total score than the more proximal or distal domains.</div></div>\",\"PeriodicalId\":19135,\"journal\":{\"name\":\"Neuromuscular Disorders\",\"volume\":\"43 \",\"pages\":\"Article 104441.55\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuromuscular Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960896624002281\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromuscular Disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960896624002281","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
213P Sensitivity to change of the motor function measure (MFM) in myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is a hereditary multisystemic disease characterized by progressive muscle wasting, heart conduction abnormalities, early-onset cataract, and endocrinological disorders. It is caused by a non-coding CTG repeat expansion in the DMPK gene. With new therapeutic advancements and ongoing clinical trials focusing on siRNA, antisense oligonucleotides or gene therapy, there is an imperative to identify a suitable clinical outcome to assess motor function in DM1. The Motor Function Measure is a 3-dimensional quantitative scale (D1: standing/transfers, D2: Proximal/axial, D3: Distal) designed to monitor motor function in patients with neuromuscular diseases encompassing the spectrum of the disease regardless disease severity or functional level. This is a multicentric retrospective review of adults and children with a genetic diagnosis of DM1. Included subject were male or female DM1 patients with the availability of at least 2 MFM32 scores at 1 year. MFM32’s mean slope of change and standard response mean (SRM) were calculated. 343 subjects were included. At the first MFM mean age was 36.3 years (+/- 16.1, min: 6.1yo; max: 71.8yo), and mean MFM32 scores were 69.1%+/-25.1, 91.9%+/-9.1, 90.8.1%+/-8.4, and 82.4%+/-13.8 for D1, D2, D3 and Total score respectively. Average time between first and last assessments was 5.1 years (+/- 3.6, min: 1 y; max: 15.9yo). MFM32’s yearly mean slope of change was -2.25% (+/-3.86) for D1, -1.09% (+/-3.50) for D2, -0.54% (+/-2.95) for D3, -1.44 (+/-2.46) for total score. SRM was -0.58 for D1, -0.31 for D2, -0.18 for D3, -0.59 for total score. Understanding the change over time in a natural history cohort is important to understand the impact of change against a changing disease landscape. We showed MFM32’s responsiveness to change most relevant in the standing and transfer domain (D1) and MFM total score than the more proximal or distal domains.
期刊介绍:
This international, multidisciplinary journal covers all aspects of neuromuscular disorders in childhood and adult life (including the muscular dystrophies, spinal muscular atrophies, hereditary neuropathies, congenital myopathies, myasthenias, myotonic syndromes, metabolic myopathies and inflammatory myopathies).
The Editors welcome original articles from all areas of the field:
• Clinical aspects, such as new clinical entities, case studies of interest, treatment, management and rehabilitation (including biomechanics, orthotic design and surgery).
• Basic scientific studies of relevance to the clinical syndromes, including advances in the fields of molecular biology and genetics.
• Studies of animal models relevant to the human diseases.
The journal is aimed at a wide range of clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.